Heart fat targeted drug for improving atrial fibrillation outcomes
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had persistent atrial fibrillation (a type of irregular heartbeat) that has lasted more than 7 days but no longer than 5 years.
- This is your first planned procedure to correct the rhythm (catheter ablation).
- You do not have diabetes, heart failure, or chronic kidney disease.
- A heart CT or MRI shows extra fat around the heart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
This study tests whether a daily medication called dapagliflozin (usually used for diabetes) can improve the success of rhythm control (treatments that bring your heartbeat back to normal) in people with recent atrial fibrillation. If you join, you would receive either the study drug or a placebo along with standard care.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.